Everest Medicines Announces Positive Preliminary Results for Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025 Congress

Reuters
06-09
Everest Medicines Announces Positive Preliminary Results for Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025 Congress

Everest Medicines Ltd. has announced positive results from its ongoing Phase 1b/2a clinical trial for EVER001, a next-generation covalent reversible Bruton's tyrosine kinase $(BTK.AU)$ inhibitor, aimed at treating primary membranous nephropathy (pMN) and other autoimmune renal diseases. The results were presented in a focused oral session at the 62nd Congress of the European Renal Association (ERA 2025). EVER001 was found to be generally safe and well tolerated, with no clinically significant adverse events typically linked to covalent irreversible BTK inhibitors, such as bleeding or severe liver function impairment. This trial marks a significant step as there is currently no globally approved drug for pMN, and EVER001 has the potential to provide new treatment options for over 10 million patients worldwide. The company plans to continue the global clinical development of EVER001.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN05660) on June 09, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10